HBIO Stock - Harvard Bioscience, Inc.
Unlock GoAI Insights for HBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $94.14M | $112.25M | $113.33M | $118.90M | $102.10M |
| Gross Profit | $54.77M | $66.07M | $60.82M | $67.65M | $58.04M |
| Gross Margin | 58.2% | 58.9% | 53.7% | 56.9% | 56.8% |
| Operating Income | $-6,211,000 | $1.89M | $-6,933,000 | $2.07M | $221,000 |
| Net Income | $-12,405,000 | $-3,415,000 | $-9,516,000 | $-288,000 | $-7,810,000 |
| Net Margin | -13.2% | -3.0% | -8.4% | -0.2% | -7.6% |
| EPS | $-0.28 | $-0.08 | $-0.23 | $-0.01 | $-0.20 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 9th 2025 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| March 10th 2023 | The Benchmark Company | Upgrade | Buy | $4← $3 |
Earnings History & Surprises
HBIOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $0.04 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.04 | $-0.01 | -128.6% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.03 | $-0.01 | +60.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.05 | $-0.02 | -140.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.05 | $-0.03 | -160.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $0.02 | $0.02 | -14.3% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $0.05 | $0.04 | -20.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $0.04 | $0.01 | -75.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.05 | $0.04 | -20.0% | ✗ MISS |
Q2 2023 | Apr 25, 2023 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $0.03 | $0.04 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.05 | $-0.01 | -120.0% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.06 | $0.05 | -16.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.05 | $0.04 | -20.0% | ✗ MISS |
Q1 2022 | Mar 8, 2022 | $0.09 | $0.08 | -11.1% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $0.06 | $0.06 | 0.0% | = MET |
Q3 2021 | Aug 5, 2021 | $0.05 | $0.06 | +20.0% | ✓ BEAT |
Latest News
Harvard Bioscience shares are trading higher after the company announced an agreement with BroadOak Capital to provide a $40 million credit facility.
📈 PositiveHarvard Bioscience Strikes Agreement With BroadOak Capital Partners To Offer $40M Credit Facility Of Three Term Loans
📈 PositiveHarvard Bioscience Sees Q4 Sales $22.500M-$24.500M vs $23.100M Est
➖ NeutralHarvard Bioscience Q3 Sales $20.591M Beat $20.000M Estimate
📈 PositiveHarvard Bioscience Granted 180 Days Or Until March 30, 2026 By Nasdaq For Compliance
➖ NeutralHarvard Bioscience shares are trading higher after the company announced he expansion of its distribution agreement with Fisher Scientific.
📈 PositiveHarvard Bioscience Expands Distribution Agreement With Fisher Scientific To U.S., Adding Pumps, Spectrophotometers And Electroporation Systems To Catalog
📈 PositiveBenchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2
➖ NeutralHarvard Bioscience Tops Q2 Revenue Views
📈 PositiveFrequently Asked Questions about HBIO
What is HBIO's current stock price?
What is the analyst price target for HBIO?
What sector is Harvard Bioscience, Inc. in?
What is HBIO's market cap?
Does HBIO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HBIO for comparison